NCT01422486 - Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG

ezatiostat hydrochloride (Telintra®)

Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.

Trial Locations (5)

Columbia University, New York

Center for Cancer and Blood Disorders, Bethesda

Vanderbilt University, Nashville

Loyola University, Maywood

SIU School of Medicine, Simmons Cancer Center, Springfield